StemCells Inc  

(Public, NASDAQ:STEM)   Watch this stock  
Find more results for STEM
-0.01 (-0.71%)
After Hours: 1.38 -0.02 (-1.43%)
Sep 27, 5:05PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.39 - 1.42
52 week 0.33 - 7.56
Open 1.40
Vol / Avg. 0.00/5.92M
Mkt cap 17.17M
P/E     -
Div/yield     -
EPS -2.80
Shares 12.01M
Beta 0.09
Inst. own 5%

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 8582.26% -31153.25%
Operating margin -40852.13% -31619.18%
EBITD margin - -30115.66%
Return on average assets 84.99% -135.76%
Return on average equity - -1315.44%
Employees 74 -
CDP Score - -


3155 Porter Dr
PALO ALTO, CA 94304-1213
United States - Map
+1-650-4753100 (Phone)
+1-510-4564001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


StemCells, Inc. (StemCells) is engaged in the research, development and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. Its lead product development program is its central nervous system (CNS) program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology. It is in clinical development with its HuCNS-SC cells for a range of diseases and disorders of the central nervous system, which consists of the brain, spinal cord and eye. It is conducting a Phase I/II clinical trial to evaluate the safety and preliminary efficacy of its HuCNS-SC cells as a treatment for dry age-related macular degeneration (AMD). It has conducted a Radiant Study, which is a Phase II randomized, controlled proof-of-concept study, designed to evaluate both the safety and efficacy of its HuCNS-SC cells for the treatment of geographic atrophy (GA).

Officers and directors

John J. Schwartz Ph.D. Independent Chairman of the Board
Age: 80
Bio & Compensation  - Reuters
Kenneth Blair Stratton J.D. Interim President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Ann Tsukamoto Ph.D. Executive Vice President - Scientific and Strategic Alliances
Age: 62
Bio & Compensation  - Reuters
Eric H. Bjerkholt Independent Director
Age: 56
Bio & Compensation  - Reuters
Ricardo B. Levy Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters